Bio-Rad's (BIO) Clinical Diagnostics arm registers growth in Q1, primarily driven by an increased demand for quality control, blood typing, and diabetes products.
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q1 2024 Earnings Call Transcript May 7, 2024 Bio-Rad Laboratories, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good afternoon everyone, and welcome to today’s Bio-Rad First Quarter 2024 Earnings Results Conference Call. At this […]
Q1 2024 Bio Rad Laboratories Inc Earnings Call